Eli Lilly’s Retatrutide Delivers 28.3% Weight Loss, Foundayo Maintains 80%
Retatrutide achieved an average 28.3% weight reduction in Phase 3 TRIUMPH-1 over 80 weeks, with 65.3% of patients reaching non-obese BMI and improved cardiovascular markers. Lilly’s oral GLP-1 Foundayo maintained 80% of prior weight loss after 52 weeks, boosting shares by 2.4% and strengthening its stance versus Novo Nordisk’s Wegovy.
1. TRIUMPH-1 Phase 3 Results
The Phase 3 TRIUMPH-1 trial of retatrutide reported an average 28.3% reduction in body weight over 80 weeks, with 65.3% of participants achieving a non-obese BMI. These data establish retatrutide as a potential next-generation obesity therapy for Eli Lilly’s expanding metabolic portfolio.
2. Long-Term Efficacy and Cardiovascular Benefits
Extended follow-up through 104 weeks demonstrated sustained weight loss and notable improvements in cardiovascular risk markers, reinforcing retatrutide’s profile for long-term metabolic health and supporting Lilly’s path toward regulatory submissions.
3. Foundayo Oral GLP-1 Maintenance Data
In the ATTAIN-MAINTAIN study, Lilly’s oral GLP-1 therapy Foundayo preserved 80% of prior weight loss after 52 weeks, driving a 2.4% increase in Lilly shares and bolstering its competitive position against Novo Nordisk’s Wegovy in the weight-loss market.